ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bristol, VantAI Pair Technologies In Pr
ScripAscendis Pharma A/S has two approved products and plans to submit a third drug candidate for approval later this year from its endocrinology rare disease portfolio. It also has two clinical-stage can
ScripA bevy of big venture capital financings have been announced since Labor Day, the official end of summer in the US, led by a $300m series C round for Acelyrin, Inc. The boom in VC mega-deals is rema